Active substance
Pyrazinamide
- SFDA 2
- US FDA 3
- Health Canada 1
- US price lines 1
- NHS prices 1
- WHO EML 1
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| PYRAZINAMIDE ANTIBIOTICE | 500 mg | Tablet · Oral use | 100 Blister | SAR 63.40 | Generic · Prescription | ANTIBIOTIC S.E | Valid |
| PZA 500 MG TAB. | 500 mg | Tablet · Oral use | 50 Blister | SAR 33.30 | NCE · Prescription | SANDOZ | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
PERITONITIS, PERITONEAL DIALYSIS-RELATED PERITONITIS; TUBERCULOSIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PYRAZINAMIDE | 500MG | tablet · oral | NOVITIUM PHARMA | Prescription | 3 Jun 1971 |
| PYRAZINAMIDE | 500MG | tablet · oral | HIKMA PHARMS | Prescription | 30 Jun 1992 |
| PYRAZINAMIDE | 500MG | tablet · oral | MACLEODS PHARMS | Prescription | 27 Jul 2020 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| PDP-PYRAZINAMIDE | 00618810 | 500 MG | TABLET · ORAL | PENDOPHARM DIVISION OF PHARMASCIENCE INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | PYRAZINAMIDE 500 MG TABLET | $1.30807 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Pyrazinamide 500mg tablets | £40.06 | 30 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.5. Antituberculosis medicines · core
Tuberculosis
Oral > Solid > dispersible tablet: 150 mg | Oral > Solid > tablet: 400 mg; 500 mg
Safety signals and safety-related labeling changes
- US FDA 5 Dec 2025 RIFATER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.